Nature Reviews Clinical Oncology

Article	Citations
Tasadenoturev active in DIPG	1124
A new standard of care for advanced-stage urothelial carcinoma	770
From little subclones grow mighty oaks	767
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	742
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	664
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	648
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	623
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	612
Novel ICI–TKI combination improves HCC outcomes	599
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	559
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	552
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	547
The emerging roles of circRNAs in cancer and oncology	543
The immune landscape of common CNS malignancies: implications for immunotherapy	509
Hodgkin lymphoma: great progress with room for improvement	506
Gut microbiota in colorectal cancer development and therapy	464
Current understanding and management of CAR T cell-associated toxicities	461
From ESMO 2022	454
From the ESMO Congress 2021	396
Mortality is similar with active monitoring	365
Contrasting results with second-line CAR T cells in large B cell lymphoma	359
Ponatinib superior to imatinib in Ph+ ALL	357
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	356
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	350
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?	326

Sacituzumab tirumotecan improves OS in mTNBC	325
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	313
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	310
Harnessing cytokines and chemokines for cancer therapy	306
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	300
Humanized mouse models for immuno-oncology research	286
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	271
Craniospinal irradiation improves leptomeningeal metastasis control	269
Survival benefit with second-line combination in endometrial cancer	251
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	249
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	232
Biomarkers for immunotherapy of hepatocellular carcinoma	224
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	217
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	213
Improving outcomes in patients with oesophageal cancer	211
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070	209
Harnessing big data to characterize immune-related adverse events	207
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	206
Spatial landscapes of cancers: insights and opportunities	203
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	202
DREAMseq of therapy for BRAF-mutant melanoma	198
New CAPSTONE of SCLC therapy?	196
SHINE a light: frontline ibrutinib for MCL	195
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions	194
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	188
Women with clinically node negative breast cancer can safely avoid axillary surgery	185
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	175
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond	166
Aumolertinib is effective in NSCLC	163
From ESMO 2023: advances in lung cancer	162
Circulating tumour DNA — looking beyond the blood	160
Prospective comparisons support the use of navigational bronchoscopy	153
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	151
Targeting chromosomal instability in patients with cancer	149
Mitigating acute chemotherapy-associated adverse events in patients with cancer	145
Long-term outcomes following CAR T cell therapy: what we know so far	143
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	140
Benefit with ramucirumab in mesothelioma	137
Response to neoadjuvant endocrine therapy complements recurrence score	136
Multiomics STEP up in correlative analysis of response to CAR T cells	130
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	122
From the ESMO Congress 2023	121
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	120
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	118
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	117
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	117
HAIC-FO improves outcomes in HCC	117
Newly approved cancer drugs in China — innovation and clinical benefit	108
Enhancing immunotherapy with tumour-responsive nanomaterials	107
Lung cancer in patients who have never smoked — an emerging disease	103

Claudin 18.2 as a novel therapeutic target	101
Clinical implications of T cell exhaustion for cancer immunotherapy	100
From the 2021 ASCO Annual Meeting	91
Combining CAR T cells effective in RRMM	90
Targeted biopsy reduces detection of clinically insignificant cancer	90
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	87
Translating biological insights into improved management of endometrial cancer	85
Less-frequent surveillance is noninferior to annual mammography	84
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	83
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	82
Barriers in access to oncology drugs — a global crisis	81
Two decades of advances in clinical oncology — lessons learned and future directions	78
BrECADD raises the bar in classical Hodgkin lymphoma	77
HSCT prolongs remission of high-risk CTCLs	75
Nirogacestat effective in desmoid tumours	71
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	71
Promise with co-administration of CAR T cells	71
GPRC5D-CAR T cells active in MM	70
Promising OS with oncolytic virotherapy	68
Efficacy of TILs confirmed	67
Thermal ablation is safer than resection of colorectal liver lesions	65
Exploiting bacteria for cancer immunotherapy	61
Uncovering adagrasib resistance	61
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	60
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	59
The current state of the art and future trends in RAS-targeted cancer therapies	57
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	56
Repotrectinib effective in ROS1-fusion-positive NSCLC	55
Neoadjuvant pembrolizumab improves outcomes	53
MSI-H/dMMR mCRC: ICIs in the first line?	52
177Lu–PSMA-PET extends survival	52
Pembrolizumab tunes up chemotherapy in cervical cancer	51
KN046 shows tolerability and activity in TNBC	50
Belzutifan is active in VHL-related cancers	50
Author Correction: Anaplastic glioma: benefit of temozolomide clarified	50
LAG3 inhibition improves outcomes	50
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	47
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	46
Problematic crossovers in cancer drug trials	46
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	44
Integrated MRI-guided radiotherapy — opportunities and challenges	42
The emerging roles of γδ T cells in cancer immunotherapy	41
CAR T cells induce durable remission of neuroblastoma	39
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	38
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	34
National value-based pricing negotiation for oncology drugs — lessons from China	33
Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	33
Axicabtagene effective in indolent NHL	33
Personalizing adjuvant therapy for patients with colorectal cancer	32
GPRC5D as a novel immunotherapeutic target in multiple myeloma	32
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	31
Therapeutic targeting of the hypoxic tumour microenvironment	30
Laparoscopic TME is non-inferior	29
Epcoritamab is active in large B cell lymphomas	28
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM	27
Menin–KMT2A interaction inhibitor shows promise	26
Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer	26
MajesTEC results with teclistamab in RRMM	25
Laparoscopic hemihepatectomy is safe and effective	25
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia	23
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	22
The age of foundation models	22
Adjuvant chemotherapy improves OS in UTUC	21
Pembrolizumab for HER2+ gastric cancer	20
FOLFOX–HAIC active in large HCC	20
Synthetic lethal strategies for the development of cancer therapeutics	19
HER2-targeted therapies beyond breast cancer — an update	17
Early promising results with the novel KRASG12C inhibitor divarasib	17
Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma	17
Platinum-ineligible: atezolizumab preferable	17
Pembrolizumab reduces recurrence risk in stage II melanoma	15
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?	14
Will I feel better? Raising the bar for quality of life in oncology	13
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics	13
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients	13
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?	13
Precision oncology for KRASG12C-mutant colorectal cancer	13
Getting the right combination to break the epigenetic code	13
Engaging results with glofitamab in DLBCL	12
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	12

Cancer mRNA vaccines: clinical advances and future opportunities	12
SBRT feasible for oligometastatic RCC	12
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways	12
T-DXd is effective after T-DM1	11
Docetaxel-based CRT improves survival in cisplatin-ineligible patients	11
Benefit from huCAR19-IL18 cells in patients with CD19+ lymphomas after CAR T cells	10
Fertility support for patients with gynaecological cancers — a vital but neglected issue	10
Thermal immuno-nanomedicine in cancer	10
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data	10
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck	10
Risk-adjusting away volume as a quality metric for surgical oncology: a perspective worth re-visiting	10
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer	9
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges	9
Dabrafenib–trametinib moves to the first line in low-grade glioma	9
Finding the Goldilocks zone in neoadjuvant radioimmunotherapy	8
Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer	8
Abemaciclib crowned in monarchE	8
Molecular tumour boards — current and future considerations for precision oncology	7
Gut microbes as biomarkers of ICI response — sharpening the focus	7
New treatment strategies for advanced-stage gastrointestinal stromal tumours	7
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks	7
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer	7
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	7
Cerebrospinal fluid liquid biopsies for medulloblastoma	7
Targeting cuproplasia and cuproptosis in cancer	6
Is NETTER-2 a practice-changing trial?	6
Nasopharyngeal carcinoma: an evolving paradigm	6
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent	6
A new era for glioma therapy — targeting mutant IDH	6
SUNLIGHT illuminates the activity of bevacizumab	5
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3	5
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	5
Synergy of EphB2 and PD-1 blockade	5
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins	5
Dostarlimab effective in dMMR LARC	5
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	5
Benefit with adjuvant metronomic capecitabine in NPC	5
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	4
Prospective insights on the use of bTMB	4
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL	4
Early promising results with addition of an ICI and an anti-angiogenic to TACE	4
FDA approvals in 2024: new options for patients across cancer types and therapeutic classes	4
Maintenance capecitabine is beneficial in NPC	4
Criteria for the translation of radiomics into clinically useful tests	4
Promising results with zongertinib in advanced-stage HER2-mutant NSCLC	4
KTE-X19 efficacious in adults with B-ALL	4
Asciminib is safe and effective in patients with newly diagnosed CML	4
Adjuvant S-1 extends OS in biliary tract cancers	4
Transanal TME noninferior to the laparoscopic approach	4
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer	4
Targeting the glioblastoma resection margin with locoregional nanotechnologies	4
T-DXd effective in HER2-mutant NSCLC	4
Circulating tumour cells for early detection of clinically relevant cancer	4
Blinatumomab improves outcomes in infant ALL	4
AI accurately identifies targetable alterations in lung cancer histological images	4
The SONIA trial shows the power and challenges of academic research	4
Darolutamide combo is a sensible option for mHSPC	4
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions	4
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy	3
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach	3
Novel combination delivers prolonged OS	3
Rare molecular subtypes of lung cancer	3
Progress in systemic therapy for advanced-stage urothelial carcinoma	3
Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?	3
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours	3
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	3
Novel assessment of epigenetic imprinting biomarkers for the diagnosis of thyroid nodules	3
Adjuvant nivolumab shows promise in MCC	3
Envisioning trans-inclusive and trans-specific cancer care	3
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?	3
Towards equitable AI in oncology	3
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer	3
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology	3
Benefit with ESCAT-guided treatment	3
Radiotherapy can be omitted for older patients with low-risk disease	3
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome	3
Tovorafenib effective against low-grade gliomas harbouring BRAF fusions	3
Tebentafusp for uveal melanoma	3
Pembrolizumab improves EFS in TNBC	3
Leptomeningeal metastatic disease: new frontiers and future directions	3
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?	3
Tumour antigen-induced T cell exhaustion — the archenemy of immune-hot malignancies	3
Extended neoadjuvant dostarlimab provides durable benefit in resectable dMMR solid tumours	3
CABINET presents cabozantinib as a new treatment option for NETs	3
The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain	3
Sotorasib effective in KRAS-mutant NSCLC	3
Author Correction: Clinical relevance of tumour-associated macrophages	3
Clinical relevance of tumour-associated macrophages	3
Emerging importance of HER3 in tumorigenesis and cancer therapy	3
From WCC 2022	3
Second-line axi-cel improves overall survival	3
From ASCO 2023	2
HPV-associated oropharyngeal cancer — discussion points	2
Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy	2
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’	2